Itraconazole-terbinafine compound injection for dogs and cats and preparation method of compound injection

The technology of itraconazole and injection is applied in the field of itraconazole-terbinafine compound injection for dogs and cats and its preparation field, which can solve the problems of fast acting time, short bioavailability, poor stability and the like , to achieve the effect of high drug concentration, high inclusion rate and good stability

Inactive Publication Date: 2016-06-22
黑龙江省兽医科学研究所
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In clinical practice, many drugs have poor stability, low bioavailability, fast drug effect and short acting time, etc.,...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Itraconazole-terbinafine compound injection for dogs and cats and preparation method of compound injection
  • Itraconazole-terbinafine compound injection for dogs and cats and preparation method of compound injection
  • Itraconazole-terbinafine compound injection for dogs and cats and preparation method of compound injection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] The invention discloses a method for preparing itraconazole-terbinafine compound injection for dogs and cats. The specific steps are as follows:

[0017] Step 1: Accurately weigh 1.0 g of itraconazole and 1.0 g of terbinafine into beaker A and beaker B respectively, divide hydroxypropyl-β-cyclodextrin into two parts, and put them into beaker C (containing hydroxyl Propyl-β-cyclodextrin 20~25g) and beaker D (containing hydroxypropyl-β-cyclodextrin 10~15g), add propylene glycol 5mL into beaker A, then slowly add 12mol·L -1 Concentrated hydrochloric acid 370μL to completely dissolve itraconazole; add 3mL of absolute ethanol to beaker B to completely dissolve terbinafine; pour double-distilled water into beaker C (containing 24-30mL of double-distilled water) and beaker D (containing Dissolve hydroxypropyl-β-cyclodextrin in 12-18 mL of double distilled water.

[0018] Step 2: Under the condition of magnetic stirring, slowly drop the itraconazole solution in beaker A into b...

Embodiment 2

[0022] Experimental purpose and method: In order to characterize the chemical relationship between hydroxypropyl-β-cyclodextrin, itraconazole and terbinafine, this example uses ultraviolet absorption spectrum to characterize and analyze the synthetic preparation. The experimental operation is consistent with the relevant standard operation, and will not be repeated here.

[0023] Experimental results: if figure 1 As shown, use a microplate reader to carry out wavelength scanning of the compound injection and perform absorption band scanning in the range of 250nm to 310nm (λ), by figure 1 It can be seen that the drug in the compound injection forms peaks at 262nm and 289nm, indicating that itraconazole and terbinafine did not react, but formed inclusion complexes with hydroxypropyl-β-cyclodextrin respectively.

Embodiment 3

[0025] Experimental purpose and method: In order to characterize the biological toxicity of the preparation of the present application, this example established a mouse model, and carried out an acute toxicity test and a subchronic toxicity test. The specific experimental methods are as follows: Acute toxicity test: after pre-experimentation, compound injection The median lethal dose (LD50) of terbinafine in solution is higher than that of itraconazole, so the dosage is calculated by itraconazole. 70 mice were randomly divided into 7 groups, 10 in each group, half male and half male, and kept in separate cages. Among them, the seventh group is the control group (injection of normal saline). The doses of the mice in each group were determined on the basis of the pre-test, and the dose ratio between two adjacent groups was 1.4. The specific doses of the mice in each group are shown in Table 1. Press 0.03mL·g for each mouse -1 Subcutaneous injection on the back of the body weig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of veterinary drugs, and discloses an itraconazole-terbinafine compound injection for dogs and cats and a preparation method of the compound injection.The novel compound preparation prepared by taking hydroxypropyl-beta-cyclodextrin as a carrier has the advantages of being wide in antibacterial spectrum, high in treatment effect, low in cost and the like; the product is high in inclusion rate and drug concentration, capable of meeting the treatment requirement and good in stability; the compound injection is low in toxicity, good in absorption and capable of achieving the better treatment effect on fungal skin diseases of the dogs and the cats.

Description

technical field [0001] The invention relates to the field of veterinary drugs, in particular to an itraconazole-terbinafine compound injection for dogs and cats and a preparation method thereof. Background technique [0002] The controlled release of drugs is a new multidisciplinary field developed in recent decades. With the emergence of a large number of polymer materials, their application in the research and production of pharmaceutical preparations is becoming more and more extensive. It can be said that every progress in the use of polymer materials will have a great impetus to the development of pharmaceutical preparations, making a qualitative leap in the quality of pharmaceutical preparations. The emergence of these materials makes the controlled release and sustained release of drugs possible. Realize, have important advantage with the common pharmaceutical preparation in the past. At the same time, it is also because of clinical needs that drug controlled releas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/496A61K31/137A61K47/48A61K9/08A61P31/02A61P31/10A61P17/00
CPCA61K9/0019A61K9/08A61K31/137A61K31/496A61K47/02A61K2300/00
Inventor 陈亮潘文王伟郭影成李旭东徐兵刘博超
Owner 黑龙江省兽医科学研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap